A high expression of CD109 correlates with poor prognosis and chemoresistance in patients harboring EOC [16], but the role of CD109 in the drug resistance of ovarian cancer cells and its underlying mechanism remain largely unknown. This evidence concerns the gene CD109 and ovarian carcinoma.